Corcept Therapeutics to Present New Data from Pivotal ROSELLA Trial on Relacorilant for Platinum-Resistant Ovarian Cancer at ESMO 2025

Reuters

2025/09/23

Corcept <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present New Data from Pivotal ROSELLA Trial on Relacorilant for Platinum-Resistant Ovarian Cancer at ESMO 2025

Corcept Therapeutics Incorporated has announced that it will present new data from its pivotal Phase 3 ROSELLA trial at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. The study focuses on the use of relacorilant in combination with nab-paclitaxel in patients with platinum-resistant ovarian cancer who were previously treated with a PARP inhibitor. This patient population is noted for having a particularly poor prognosis. The data will be shared during a late-breaking mini oral session on October 19, 2025. The ROSELLA trial is being conducted in collaboration with several international oncology groups, including The GOG Foundation, Inc., ENGOT, APGOT, LACOG, and ANZGOG.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922541539) on September 22, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2569732377"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569732377\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569732377?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 02:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569732377","market":"us","top_or_hot":-1,"title":"Corcept Therapeutics to Present New Data from Pivotal ROSELLA Trial on Relacorilant for Platinum-Resistant Ovarian Cancer at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present New Data from Pivotal ROSELLA Trial on Relacorilant for Platinum-Resistant Ovarian Cancer at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Corcept Therapeutics Incorporated has announced that it will present new data from its pivotal Phase 3 ROSELLA trial at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. The study focuses on the use of relacorilant in combination with nab-paclitaxel in patients with platinum-resistant ovarian cancer who were previously treated with a PARP inhibitor. This patient population is noted for having a particularly poor prognosis. The data will be shared during a late-breaking mini oral session on October 19, 2025. The ROSELLA trial is being conducted in collaboration with several international oncology groups, including The GOG Foundation, Inc., ENGOT, APGOT, LACOG, and ANZGOG.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922541539) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept Therapeutics to Present New Data from Pivotal ROSELLA Trial on Relacorilant for Platinum-Resistant Ovarian Cancer at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept Therapeutics to Present New Data from Pivotal ROSELLA Trial on Relacorilant for Platinum-Resistant Ovarian Cancer at ESMO 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-23 02:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present New Data from Pivotal ROSELLA Trial on Relacorilant for Platinum-Resistant Ovarian Cancer at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Corcept Therapeutics Incorporated has announced that it will present new data from its pivotal Phase 3 ROSELLA trial at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. The study focuses on the use of relacorilant in combination with nab-paclitaxel in patients with platinum-resistant ovarian cancer who were previously treated with a PARP inhibitor. This patient population is noted for having a particularly poor prognosis. The data will be shared during a late-breaking mini oral session on October 19, 2025. The ROSELLA trial is being conducted in collaboration with several international oncology groups, including The GOG Foundation, Inc., ENGOT, APGOT, LACOG, and ANZGOG.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922541539) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文藝復興科技持倉","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL1r9HL1:1","article_id":"2569732377","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569732377","pubTimestamp":1758565817,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Corcept Therapeutics to Present New Data from Pivotal ROSELLA Trial on Relacorilant for Platinum-Resistant Ovarian Cancer at ESMO 2025. Corcept Therapeutics Incorporated has announced that it will present new data from its pivotal Phase 3 ROSELLA trial at the 2025 European Society for Medical Oncology  Annual Meeting. The study focuses on the use of relacorilant in combination with nab-paclitaxel in patients with platinum-resistant ovarian cancer who were previously treated with a PARP inhibitor. This patient population is noted for having a particularly poor prognosis. The data will be shared during a late-breaking mini oral session on October 19, 2025. The ROSELLA trial is being conducted in collaboration with several international oncology groups, including The GOG Foundation, Inc., ENGOT, APGOT, LACOG, and ANZGOG.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4007":"制药","CORT":"Corcept医疗","LU0566484027.USD":"安本美国小盘成长股"},"translate_title":"Corcept Therapeutics将在ESMO 2025上展示Relacorilant治疗铂类耐药卵巢癌的关键ROSELLA试验的新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":0.9},"content_text":"Corcept Therapeutics to Present New Data from Pivotal ROSELLA Trial on Relacorilant for Platinum-Resistant Ovarian Cancer at ESMO 2025\n    \n\n        Corcept Therapeutics Incorporated has announced that it will present new data from its pivotal Phase 3 ROSELLA trial at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. The study focuses on the use of relacorilant in combination with nab-paclitaxel in patients with platinum-resistant ovarian cancer who were previously treated with a PARP inhibitor. This patient population is noted for having a particularly poor prognosis. The data will be shared during a late-breaking mini oral session on October 19, 2025. The ROSELLA trial is being conducted in collaboration with several international oncology groups, including The GOG Foundation, Inc., ENGOT, APGOT, LACOG, and ANZGOG.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922541539) on September 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}